MK0767 Glipizide Comparator Cardiac Safety Study (0767-018)

Merck Sharp & Dohme (MSD)

Status and phase: Terminated; Phase 3

Conditions: Diabetes Mellitus, Type 2

Treatments: Drug: MK0767

Study type: Interventional

Funder types: Industry

Identifiers

NCT00543010

0767-018

2007_644

Details and patient eligibility

About

A study to evaluate the cardiac and metabolic effects of MK0767 in patients with Type 2 Diabetes.

This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Enrollment: 247 patients

Sex: All

Ages: 21 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• You are taking at least one medication for high blood sugar
• Age 21 to 80

Exclusion criteria

• History of Type 1 Diabetes Mellitus
• Currently on estrogen replacement therapy regimen
• Currently on a weight loss program with ongoing weight loss or taking medications for weight loss
• Having surgery 30 days before starting the study
• Have taken any other investigational drug in the past 90 days
• Have Hepatitis B or C
• Active liver or gallbladder disease

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind